Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

NANot yet recruitingINTERVENTIONAL

Enrollment

2,100

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

October 15, 2029

Study Completion Date

October 15, 2030

Conditions

Coronary Artery Disease

Interventions

DEVICE

ihtDEStiny® DES implanted

DEVICE

Xience™ DES implanted

All Listed Sponsors

lead

Fundación EPIC

OTHER